Legal & General Group
SER icon

Legal & General Group’s Serina Therapeutics SER Stock Holding History

Legal & General Group’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-126
Closed -$4K – 3477
2020
Q1 		$4K Hold
126
– – ﹤0.01% 3292
2019
Q4 		$8K Buy
126
+25
+25% +$1.35K ﹤0.01% 3318
2019
Q3 		$7K Hold
101
– – ﹤0.01% 3307
2019
Q2 		$13K Buy
101
+67
+197% +$9.07K ﹤0.01% 3317
2019
Q1 		$5K Hold
34
– – ﹤0.01% 3313
2018
Q4 		$4K Buy
+34
New +$4.32K ﹤0.01% 3354

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Legal & General Group's SER Position: Q2 2020 in Review

Legal & General Group sold out of Serina Therapeutics (SER) in Q2 2020, closing a stake of 126 shares — an estimated $4K sold.

Legal & General Group first reported a position in SER in Q4 2018 and held it in 6 quarters. The position peaked at $13K in Q2 2019. 48 funds tracked by Wall St. Rank hold SER as of Q2 2020.

  • Legal & General Group reported no remaining Serina Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Legal & General Group sold 126 Serina Therapeutics shares in Q2 2020, an estimated $4K.
  • Legal & General Group first reported a position in Serina Therapeutics in Q4 2018 and held it in 6 quarters.
  • Legal & General Group's Serina Therapeutics position peaked at $13K in Q2 2019.
  • 48 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2020.

Based on Legal & General Group's 13F filing for Q2 2020, filed 14 Aug 2020.